A Comparison of Two Initial Dosing Formulas

Overview

This study will evaluate two methods of starting basal insulin to see which method may achieve a faster-to-goal titration.

Full Title of Study: “A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2011

Detailed Description

The current recommended starting dose of basal insulin in type 2 diabetes is either a fixed dose, e.g. 10 U, or a weight-based formulas, 0.1-0.2 U/kg. The estimate of eventual titration dose to attempt to reach a fasting glucose goal is 0.49 U/kg. Those many weeks of dosage upward titration are required. The investigators propose to compare the current recommended weight based, 0.1 U/kg to a correction factor derived formula. Starting with an insulin tolerance test estimation of basal dose, one would arrive at the eventual titrated basal insulin dose in significantly less days than starting at a starting dose estimate of 0.1 U/kg. Further, there would be no significant increase in overall reported hypoglycemia.

Interventions

  • Drug: Insulin detemir
    • Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.

Arms, Groups and Cohorts

  • Other: Insulin determir

Clinical Trial Outcome Measures

Primary Measures

  • Days to reach the titration target
    • Time Frame: 12 weeks
    • The number of days for the subject to reach the titration target blood sugar of 110 ml/dl

Secondary Measures

  • The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period
    • Time Frame: 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Type 2 diabetes 2. Age 18 years and above 3. Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ± glinides 4. A1c ≥ 7.0% but ≤ 10% 5. Capable of self monitoring glucose ≥4/day 6. Previously compliant with clinical recommendations 7. Fasting blood glucose ≥ 150 mg/dl 8. BMI ≤ 45 kg/m2 Exclusion Criteria:

1. Urinary ketosis 2. Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatinine >1.5 mg/dl), glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistant of another) 3. Currently participating in another clinical trial 4. Known or suspected allergy to insulin determir 5. Using insulin 6. Pregnancy or nursing or the intention of becoming pregnant or not using adequate 7. Significant liver or heart failure.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Diabetes Care Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Allen B. King, MD, Principal Investigator – Diabetes Care Center
  • Overall Official(s)
    • Allen B King, MD, Principal Investigator, Diabetes Care Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.